Bio/Pharma News

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

March 17, 2023

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Pfizer to Acquire Seagen in $43 Billion Blockbuster Deal

March 16, 2023

Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.

How Banning TiO2 Might Impact Pharma

March 15, 2023

The impact of the potential ban would have serious consequences for the availability of many drugs for European patients.

Acadia Pharmaceuticals Receives FDA Approval for First Treatment for Rare Genetic Disorder

March 14, 2023

FDA has approved Acadia Pharmaceuticlas’ Daybue (trofinetide), the first treatment for Rett syndrome, a rare genetic disorder.

FDA Approves Pfizer’s New Migraine Nasal Spray

March 14, 2023

FDA has approved Pfizer’s ZAVZPRET (zavegepant), a new nasal spray treatment for migraine.

Sumitovant Acquires Myovant for $1.7 Billion

March 14, 2023

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Biotech Companies Deal with Silicon Valley Bank Collapse

March 13, 2023

Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.

Catalent Expands UpTempo AAV Platform

March 09, 2023

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.

Merck Releases Data on Rare Blood Vessel Disorder Treatment

March 08, 2023

Sotatercept, a drug candidate acquired by Merck in an $11.5 billion acquisition, showed statistically significant improvements in various measures.

Janssen Receives Positive Opinion for AKEEGA Plus Prednisone or Prednisolone

March 08, 2023

Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.